Evolutionary cost analysis of valsartan initiation among patients with hypertension: a time series approach

References

• Alcocer L, Cueto L. Hypertension, a health economics perspective. Ther Adv Cardiovasc Dis 2008;2:147–55
   PubMedGoogle Scholar
• Boivin JM, Zannad F. [Official recommendations and guidelines for the management and reimbursement of severe hypertension as a chronic disease]. Presse Med Apr 2009;38:652–60
   PubMed Web of Science ®Google Scholar
• McManus F, Freel EM, Connell JM. Hypertension. Scott Med J 2007;52:36–42; quiz 42, 54
   PubMed Web of Science ®Google Scholar
• Mendis S, Lindholm LH, Mancia G, et al. World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens 2007;25:1578–82
   PubMed Web of Science ®Google Scholar
• Zuccala A. [Guidelines for management of hypertension: why doesn't evidence lead to unanimity?]. G Ital Nefrol 2009;26:226–35
   PubMedGoogle Scholar
• Volpe M, Tocci G. 2007 ESH/ESC Guidelines for the management of hypertension, from theory to practice: global cardiovascular risk concept. J Hypertens 2009;27(3 Suppl):3–11
   PubMedGoogle Scholar
• Clark CE, Campbell JL. Hypertension guidelines. Br J Gen Pract 2009;59:448–9; author reply 449
   PubMed Web of Science ®Google Scholar
• Segura J, Ruilope LM. New guidelines of the European Society of Hypertension. Curr Hypertens Rep 2008;10:337–8
   PubMed Web of Science ®Google Scholar
• Kaplan NM. Guidelines for the management of hypertension. Can J Cardiol 2000;16:1147–52
   PubMed Web of Science ®Google Scholar
• Donner-Banzhoff N, Echterhoff HH, Hense HW, et al. [Guidelines Clearing House Statement “Hypertension”. Summary and recommendations for a rational hypertension guideline in Germany]. Z Arztl Fortbild Qualitatssich 2000;94:341–9
   PubMedGoogle Scholar
• Ferdinand KC, Saunders E. Hypertension-related morbidity and mortality in African Americans–why we need to do better. J Clin Hypertens (Greenwich) 2006;8(1 Suppl):21–30
   PubMedGoogle Scholar
• Bardage C, Isacson DG. Self-reported side-effects of antihypertensive drugs: an epidemiological study on prevalence and impact on health-state utility. Blood Press 2000;9:328–34
   PubMed Web of Science ®Google Scholar
• Cheung BM, Wong YL, Lau CP. Queen Mary Utilization of Antihypertensive Drugs Study: side-effects of antihypertensive drugs. J Clin Pharm Ther 2005;30:391–9
   PubMed Web of Science ®Google Scholar
• Cordoba Garcia R. [Side effects of antihypertensive drugs]. Aten Primaria 1996;17:420–4
   PubMedGoogle Scholar
• Juergens JL. Side effects of antihypertensive drugs. Proc Staff Meet Mayo Clin 1958;33:317–22
   PubMed Web of Science ®Google Scholar
• Coca A. Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers). Clin Drug Investig 2008;28:211–20
   PubMed Web of Science ®Google Scholar
• Dina R, Jafari M. Angiotensin II-receptor antagonists: an overview. Am J Health Syst Pharm 2000;57:1231–41
   PubMed Web of Science ®Google Scholar
• Holwerda NJ, Fogari R, Angeli P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996;14:1147–51
   PubMed Web of Science ®Google Scholar
• McInnes GT. Clinical advantage of valsartan. Cardiology 1999;91(1 Suppl):14–18
   PubMedGoogle Scholar
• Muller-Nordhorn J, Willich SN. Angiotensin II antagonists in the treatment of hypertension-effective and efficient? Herz 2003;28:733–7
   PubMed Web of Science ®Google Scholar
• Theodoratou D, Maniadakis N, Fragoulakis V, et al. Analysis of published economic evaluations of angiotensin receptor blockers. Hellenic J Cardiol 2009;50:105–18
   PubMed Web of Science ®Google Scholar
• Marketwire. Novartis reports higher sales and earnings in first quarter of 2008 showing healthcare portfolio well on the way to new growth cycle. 2008; Available at: http://www.marketwire.com/press-release/Novartis-International-Ag-845918.html. Accessed May 21, 2010
   Google Scholar
• Campbell D, Stanley J. Experimental and quasi-experimental designs for research. Boston, MA: Houghton Mifflin Company, 1966
   Google Scholar
• Wilcox RR, Keselman HJ. Modern robust data analysis methods: measures of central tendency. Psychol Methods 2003;8:254–74
   PubMed Web of Science ®Google Scholar
• Brufsky JW, Ross-Degnan D, Calabrese D, et al. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization. Med Care 1998;36:321–32
   PubMed Web of Science ®Google Scholar
• Adams AS, Zhang F, LeCates RF, et al. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. Arch Intern Med 2009;169:750–6
   PubMedGoogle Scholar
• Jacobson Vann JC, Christofferson S, Humble CG, et al. Pharmacist and physician satisfaction and rates of switching to preferred medications associated with an instant prior authorization program for proton pump inhibitors in the North Carolina Medicaid program. J Manag Care Pharm 2010;16:250–63
   PubMed Web of Science ®Google Scholar
• Martin BC, Chisholm MA, Kotzan JA. Isolating the cost of osteoporosis-related fracture for postmenopausal women. A population-based study. Gerontology 2001;47:21–9
   PubMed Web of Science ®Google Scholar
• Siriwardena AN, Fairchild P, Gibson S, et al. Investigation of the effect of a countywide protected learning time scheme on prescribing rates of ramipril: interrupted time series study. Fam Pract 2007;24:26–33
   PubMed Web of Science ®Google Scholar
• Law MR, Lu CY, Soumerai SB, et al. Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study. Clin Ther 2010;32:729–41; discussion 716
   PubMed Web of Science ®Google Scholar
• Hartung DM, Touchette DR, Ketchum KL, et al. Effects of a prior-authorization policy for celecoxib on medical service and prescription drug use in a managed care Medicaid population. Clin Ther 2004;26:1518–32
   PubMed Web of Science ®Google Scholar
• Zhang Y. Cost-saving effects of olanzapine as long-term treatment for bipolar disorder. J Ment Health Policy Econ 2008;11:135–46
   PubMed Web of Science ®Google Scholar
• Banerjee A, Dolado J, Galbraith J, et al. Cointegration, error correction, and the econometric analysis of non-stationary data. Oxford: Oxford University Press, 1993
   Google Scholar
• Brockwell PJ, Davis RA. Time series: theory and methods, 2nd edn. New York: Springer, 2009
   Google Scholar
• Said S, Dickey D. Testing for unit roots in autoregressive-moving average models of unknown Order. Biometrika 1984;71(3):599–607
   Web of Science ®Google Scholar
• Chakravarti I, Laha R, Roy J. Handbook of methods of applied statistics. Vol. 1: John Wiley and Sons, New York, 1967
   Google Scholar
• Ljung G, Box G. On a measure of a lack of fit in time series models. Biometrika 1978;65(2):297–303
   Web of Science ®Google Scholar
• Levene H. Robust tests for equality of variances. In: Olkin I, al. HHe, eds. Contributions to probability and statistics: essays in honor of Harold Hotelling. Standford University Press, 1960. p 278–292
   Google Scholar
• Bozdogan H. Model selection and Akaike’s Information Criterion (AIC): the general theory and its analytical extensions. Psychometrika 1987;52:345–70
   Web of Science ®Google Scholar
• Bramlage P, Durand-Zaleski I, Desai N, et al. The value of irbesartan in the management of hypertension. Expert Opin Pharmacother 2009;10:1817–31
   PubMed Web of Science ®Google Scholar
• Smith DG, Nguyen AB, Peak CN, et al. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria. J Manag Care Pharm 2004;10:26–32
   PubMedGoogle Scholar
• Taylor M, Scuffham PA, Chaplin S, et al. An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors. Value Health 2009;12(4)
   Web of Science ®Google Scholar
• Coyle D, Rodby RA. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. Can J Cardiol 2004;20:71–9
   PubMed Web of Science ®Google Scholar
• Szucs TD, Sandoz MS, Keusch GW. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland–an analysis of the RENAAL study. Swiss Med Wkly 2004;134:440–7
   PubMed Web of Science ®Google Scholar
• Ekman M, Bienfait-Beuzon C, Jackson J. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden. J Hum Hypertens 2008;22:845–55
   PubMed Web of Science ®Google Scholar
• Saito I, Fujikawa K, Saruta T. Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study. Hypertens Res 2008;31:1399–405
   PubMed Web of Science ®Google Scholar
• Saito I, Saruta T. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study. Hypertens Res 2006;29:789–96
   PubMed Web of Science ®Google Scholar
• Anderson AN, Wessels F, Moodley I, et al. AT1 receptor blockers–cost-effectiveness within the South African context. S Afr Med J 2000;90:494–8
   PubMed Web of Science ®Google Scholar
• Gellad WF, Huskamp HA, Phillips KA, et al. Angiotensin receptor blockers on the formularies of Medicare drug plans. J Gen Intern Med 2007;22:1172–5
   PubMed Web of Science ®Google Scholar
• Belsey JD. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen. Curr Med Res Opin 2008;24:581–9
   PubMed Web of Science ®Google Scholar
• Dollar A, Brown C, Putnam D, et al. A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Clin Ther 2002;24:930–41
   PubMed Web of Science ®Google Scholar
• Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther 2009;31:447–62
   PubMed Web of Science ®Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, et al. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480–4
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Zhang J, Wu EQ, et al. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. Curr Med Res Opin 2010;26:849–60
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Ekman M, Fragoulakis V, et al. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece. Eur J Health Econ 2010;12(3):253–61
   PubMed Web of Science ®Google Scholar
• Miller LA, Wade R, Dai D, et al. Economic evaluation of four angiotensin II receptor blockers in the treatment of hypertension. Curr Med Res Opin 2010;26:1307–20
   PubMed Web of Science ®Google Scholar
• Garcia AJ, Martos F, Martin A, et al. [Do generic drugs help control expenditure on hypertension? Apropos of a case]. Gac Sanit 2004;18:137–44
   PubMedGoogle Scholar
• Boersma C, Voors AA, Visser ST, et al. Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data. Am J Cardiovasc Drugs 2010;10:49–54
   PubMed Web of Science ®Google Scholar
• Simons WR. Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan. Pharmacoeconomics 2003;21:61–74
   PubMed Web of Science ®Google Scholar
• Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment–a review. Cardiovasc Diabetol 2009;8:18
   PubMed Web of Science ®Google Scholar
• Nixon RM, Muller E, Lowy A, et al. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract 2009;63:766–75
   PubMed Web of Science ®Google Scholar
• Tzemos N, Lim PO, MacDonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. Cardiovasc Ther 2009;27:151–8
   PubMed Web of Science ®Google Scholar
• Kosch M, Levers A, Lang D, et al. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant 2008;23:2280–5
   PubMed Web of Science ®Google Scholar
• Okura T, Watanabe S, Kurata M, et al. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension. Clin Exp Hypertens 2008;30:415–22
   PubMed Web of Science ®Google Scholar
• Georgescu EF, Ionescu R, Niculescu M, et al. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009;15:942–54
   PubMed Web of Science ®Google Scholar